Compare INVE & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | ASRT |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.1M | 76.0M |
| IPO Year | 1997 | 2004 |
| Metric | INVE | ASRT |
|---|---|---|
| Price | $4.85 | $22.41 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $5.50 | ★ $18.00 |
| AVG Volume (30 Days) | 332.7K | ★ 375.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $60,219,000.00 | ★ $118,713,000.00 |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | $12.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $3.08 | $0.60 |
| 52 Week High | $5.30 | $22.58 |
| Indicator | INVE | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 84.74 |
| Support Level | $3.25 | $0.70 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.31 | 0.21 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 70.67 | 96.27 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.